EcoDrugPlus

Egl-9 Family Hypoxia Inducible Factor 1

Ensembl ID : ENSSFOG00015008300
Gene Symbol: EGLN1
3 Cross references
217 Possible Orthologues:

Egl-9 Family Hypoxia Inducible Factor 3

Ensembl ID : ENSSFOG00015032021
Gene Symbol: EGLN3
3 Cross references
201 Possible Orthologues:

Endothelial Pas Domain Protein 1b

Ensembl ID : ENSSFOG00015001376
Gene Symbol: EPAS1B
1 Cross references
212 Possible Orthologues:

Endothelin Converting Enzyme 1

Ensembl ID : ENSSFOG00015005487
Gene Symbol: ECE1
3 Cross references
230 Possible Orthologues:

Endothelin Receptor Type A

Ensembl ID : ENSSFOG00015016285
Gene Symbol: EDNRA
3 Cross references
263 Possible Orthologues:

Endothelin Receptor Type B

Ensembl ID : ENSSFOG00015031122
Gene Symbol: EDNRB
3 Cross references
196 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSSFOG00015002813
Gene Symbol: LOC108942499
3 Cross references
131 Possible Orthologues:

Endothelin Receptor Type B-Like

Ensembl ID : ENSSFOG00015025904
Gene Symbol: LOC108936664
3 Cross references
263 Possible Orthologues:

Epidermal Growth Factor Receptor

Ensembl ID : ENSSFOG00015021009
Gene Symbol: EGFR
3 Cross references
212 Possible Orthologues:

Equilibrative Nucleoside Transporter 1-Like

Ensembl ID : ENSSFOG00015004506
Gene Symbol: LOC108927137
3 Cross references
209 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 2

Ensembl ID : ENSSFOG00015013756
Gene Symbol: ERBB2
3 Cross references
198 Possible Orthologues:

Erb-B2 Receptor Tyrosine Kinase 3

Ensembl ID : ENSSFOG00015015143
Gene Symbol: ERBB3
3 Cross references
280 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).